Divisas / BCRX
BCRX: BioCryst Pharmaceuticals Inc
8.88
USD
0.08
(0.89%)
El tipo de cambio de BCRX de hoy ha cambiado un -0.89%. En este caso, el precio mínimo en el mercado ha alcanzado 8.85, mientras que el máximo ha alcanzado 9.07.
Siga la dinámica de la pareja de divisas BioCryst Pharmaceuticals Inc. El gráfico histórico le mostrará cómo ha cambiado el precio de %AssetName% en el pasado. Alternando entre diferentes marcos temporales, podrá monitorear las tendencias y la dinámica del tipo de cambio por minutos, horas, días, semanas y meses. Use esta información para predecir los cambios en el mercado y tomar decisiones comerciales fundamentadas.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
BCRX News
- Investing BioCryst Pharmaceuticals appoints Babar Ghias as CFO
- Benzinga BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering - BioCryst Pharma (NASDAQ:BCRX)
- Investing BioCryst stock rises after $264 million sale of European ORLADEYO business
- Investing BioCryst to sell European ORLADEYO business to Neopharmed for $264M
- Investing FDA extends review period for BioCryst pediatric drug application to December
- Investing BioCryst reports long-term efficacy of ORLADEYO in HAE treatment
- Investing Colombia approves BioCryst’s oral HAE treatment ORLADEYO
- Investing BioCryst at Goldman Sachs Conference: Strategic Growth and Profitability
- Seeking Alpha Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside
- Investing Netherlands approves BioCryst’s HAE drug ORLADEYO for reimbursement
- Investing biocryst pharmaceuticals extends cfo consulting agreement
- Investing BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Investing BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
- Investing BioCryst reports efficacy of HAE drug across age groups
- Investing Cantor Fitzgerald maintains overweight on Metsera shares
- Investing BioCryst to Present at Upcoming Investor Conferences
- Investing BioCryst reports ORLADEYO reduces severe HAE attack rates
- Benzinga BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors - BioCryst Pharma (NASDAQ:BCRX)
- Benzinga Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday - American Axle & Mfg Hldgs (NYSE:AXL), BioCryst Pharma (NASDAQ:BCRX)
- Seeking Alpha BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up (NASDAQ:BCRX)
- Seeking Alpha BioCryst: Upgrade To Hold On Strong 2024 Orladeyo Sales, But I Remain Skeptical
- The Motley Fool Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
- The Motley Fool BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript
- Seeking Alpha BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript
Rango diario
8.85
9.07
Rango anual
6.01
11.31
- Cierres anteriores
- 9.06
- Open
- 8.96
- Bid
- 8.88
- Ask
- 9.18
- Low
- 8.85
- High
- 9.07
- Volumen
- 4.695 K
- Cambio diario
- -0.89%
- Cambio mensual
- -1.11%
- Cambio a 6 meses
- 15.03%
- Cambio anual
- 21.64%
11 julio, viernes
08:00
ALL
- Act.
- Pronós.
- Prev.
16:00
USD
17:00
USD
- Act.
- Pronós.
- Prev.
- 425
17:00
USD
- Act.
- Pronós.
- Prev.
- 539
18:00
USD
- Act.
- Pronós.
- $-137.2 B
- Prev.
- $-316.0 B
19:30
USD
- Act.
- Pronós.
- Prev.
- 33.7 K
19:30
USD
- Act.
- Pronós.
- Prev.
- 63.4 K
19:30
USD
- Act.
- Pronós.
- Prev.
- 202.0 K
19:30
USD
- Act.
- Pronós.
- Prev.
- 234.7 K
19:30
USD
- Act.
- Pronós.
- Prev.
- -86.8 K
19:30
USD
- Act.
- Pronós.
- Prev.
- 0.7 K
19:30
USD
- Act.
- Pronós.
- Prev.
- -155.5 K
19:30
USD
- Act.
- Pronós.
- Prev.
- -92.8 K
19:30
USD
- Act.
- Pronós.
- Prev.
- 41.3 K
19:30
USD
- Act.
- Pronós.
- Prev.
- -69.6 K
19:30
USD
- Act.
- Pronós.
- Prev.
- 27.1 K